Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399)

碳素 医学 内科学 放射治疗 烟酰胺 生物标志物 肿瘤科 随机对照试验 缺氧(环境) 生物化学 化学 有机化学 氧气 酶
作者
Yee Pei Song,Hitesh B. Mistry,Joely J. Irlam,Helen R. Valentine,Lingjian Yang,Brian S. Lane,Catharine West,Ananya Choudhury,Peter Hoskin
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:110 (5): 1407-1415 被引量:86
标识
DOI:10.1016/j.ijrobp.2021.03.001
摘要

Purpose Many muscle-invasive bladder cancers are hypoxic, which limits the efficacy of radiation therapy. Hypoxia modification using carbogen and nicotinamide has been tested in a phase 3 trial, Bladder Carbogen Nicotinamide. We present mature follow-up data with biomarker predictions of outcomes. Methods and Materials Bladder Carbogen Nicotinamide is a prospective, phase 3, multicenter, randomized, 2-arm, nonblinded clinical trial. Participants were randomized to receive radical radiation therapy (RT; control arm) alone or with the addition of carbogen (98% O2; 2% CO2) and nicotinamide (CON). Patients with muscle-invasive or high-grade non–muscle invasive bladder cancer were included. Tumor tissue was collected at entry and was analyzed for tumor necrosis, hypoxia (24-gene signature), and basal and luminal tumor molecular subtypes. Overall survival (OS) and disease-free survival and relationships with biomarker status outcomes are analyzed using multivariable Cox regression and log-rank analysis. Results We analyzed 333 patients with a median follow-up of 10.3 years. The 10-year OS rates were 30% (95% confidence interval [CI], 0.23-0.39) in RT + CON patients and 24% (95% CI, 0.18-0.33) in the RT-alone patients (hazard ratio [HR], 0.80; 95% CI, 0.61-1.04; P = .08). The greatest benefit from CON was seen in patients with tumor necrosis (n = 79; 5-year OS, 53% vs. 33% in patients without tumor necrosis; HR, 0.59; 95% CI, 0.36-0.99; P = .04). Cases with a high hypoxia gene score (n = 75) had a 5-year OS rate of 51%, compared to 34% for a low score (HR, 0.64; 95% CI, 0.38-1.08; P = .09); those with the basal molecular subtype (n = 70) had a 5-year OS rate of 58%, compared to 38% for those with the luminal subtype (HR, 0.58; 95% CI, 0.32-1.06; P = .08). Conclusions Although the improvement in long-term OS in the whole population is not statistically significant, patients selected by necrosis and high hypoxia gene score benefitted from hypoxia modification. Many muscle-invasive bladder cancers are hypoxic, which limits the efficacy of radiation therapy. Hypoxia modification using carbogen and nicotinamide has been tested in a phase 3 trial, Bladder Carbogen Nicotinamide. We present mature follow-up data with biomarker predictions of outcomes. Bladder Carbogen Nicotinamide is a prospective, phase 3, multicenter, randomized, 2-arm, nonblinded clinical trial. Participants were randomized to receive radical radiation therapy (RT; control arm) alone or with the addition of carbogen (98% O2; 2% CO2) and nicotinamide (CON). Patients with muscle-invasive or high-grade non–muscle invasive bladder cancer were included. Tumor tissue was collected at entry and was analyzed for tumor necrosis, hypoxia (24-gene signature), and basal and luminal tumor molecular subtypes. Overall survival (OS) and disease-free survival and relationships with biomarker status outcomes are analyzed using multivariable Cox regression and log-rank analysis. We analyzed 333 patients with a median follow-up of 10.3 years. The 10-year OS rates were 30% (95% confidence interval [CI], 0.23-0.39) in RT + CON patients and 24% (95% CI, 0.18-0.33) in the RT-alone patients (hazard ratio [HR], 0.80; 95% CI, 0.61-1.04; P = .08). The greatest benefit from CON was seen in patients with tumor necrosis (n = 79; 5-year OS, 53% vs. 33% in patients without tumor necrosis; HR, 0.59; 95% CI, 0.36-0.99; P = .04). Cases with a high hypoxia gene score (n = 75) had a 5-year OS rate of 51%, compared to 34% for a low score (HR, 0.64; 95% CI, 0.38-1.08; P = .09); those with the basal molecular subtype (n = 70) had a 5-year OS rate of 58%, compared to 38% for those with the luminal subtype (HR, 0.58; 95% CI, 0.32-1.06; P = .08). Although the improvement in long-term OS in the whole population is not statistically significant, patients selected by necrosis and high hypoxia gene score benefitted from hypoxia modification.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
击剑男孩完成签到,获得积分10
刚刚
呜啦啦完成签到,获得积分10
刚刚
asdfsdafg发布了新的文献求助10
1秒前
1秒前
窗窗窗雨完成签到,获得积分10
2秒前
畅快代玉完成签到,获得积分10
2秒前
Luyt完成签到,获得积分10
3秒前
JOhn发布了新的文献求助10
3秒前
贾亚朋发布了新的文献求助10
3秒前
地学韦丰吉司长完成签到,获得积分10
3秒前
3秒前
4秒前
hyw完成签到,获得积分10
4秒前
李健的应助被顶刊相见采纳,获得10
4秒前
4秒前
KK完成签到,获得积分10
4秒前
simon完成签到,获得积分10
5秒前
小王小王发布了新的文献求助10
5秒前
若曦完成签到,获得积分10
5秒前
5秒前
整齐的凡梦完成签到,获得积分10
5秒前
ynglik完成签到,获得积分10
5秒前
毕加石页完成签到,获得积分10
5秒前
5秒前
Root完成签到,获得积分10
6秒前
6秒前
zq完成签到,获得积分10
6秒前
caicai完成签到,获得积分10
6秒前
Beibei完成签到 ,获得积分10
6秒前
欣喜的曼柔完成签到,获得积分10
7秒前
7秒前
NeymarYt98发布了新的文献求助10
7秒前
乐乐的应助被wenjian采纳,获得10
7秒前
7秒前
陈文海发布了新的文献求助10
7秒前
尘归尘完成签到 ,获得积分10
7秒前
忠嗣院学员完成签到 ,获得积分10
7秒前
7秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180339
求助须知:如何正确求助?哪些是违规求助? 9570391
关于积分的说明 21811279
捐赠科研通 7776418
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479091